Skip to Main content Skip to Navigation
Journal articles

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.

Abstract : The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD.
Complete list of metadata

https://hal-normandie-univ.archives-ouvertes.fr/hal-03138226
Contributor : Sabine Douville <>
Submitted on : Thursday, February 11, 2021 - 9:04:13 AM
Last modification on : Wednesday, February 24, 2021 - 10:07:20 AM

Identifiers

Collections

Citation

Pauline Wils, Philippe Seksik, Carmen Stefanescu, Stephane Nancey, Matthieu Allez, et al.. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.. Alimentary Pharmacology & Therapeutics (Suppl), 2020, ⟨10.1111/apt.16192⟩. ⟨hal-03138226⟩

Share

Metrics

Record views

36